title: Lipoprotein apheresis reduces biomarkers of plaque destabilization and cardiovascular risk.
abstract: Lipoprotein apheresis (LA) is believed to exert anti-atherosclerotic effects beyond LDL-cholesterol reduction. We investigated 22 patients undergoing regular LA on a weekly basis (group A) before (AP) and after LA procedure (EP), 15 healthy individuals (group B), and 22 hyperlipoproteinemic patients with concomitant cardiovascular end organ damage treated without LA therapy (group C). Biomarkers of endothelial inflammation (hsCRP), plaque destabilization, and rupture (sVCAM, MMP-9, PAPP-A, ADMA) were quantified. Intergroup comparison revealed a statistically significant lower MMP-9 level in group A (AP and EP) compared with group C (P < 0.01), whereas PAPP-A levels were lower in group B compared with group A and C (P = 0.04). EP ADMA-levels and EP sVCAM levels in group A were statistically lower compared with group B and C. AP and EP values comparison revealed a significant reduction for hsCRP (mean 41.0 ± 16.7%, P < 0.01), sVCAM (mean 69.6 ± 14.0%, P < 0.01), PAPP-A (mean 88.7 ± 20.4%, P < 0.01), ADMA (mean 69.7 ± 18.4% P < 0.01). In conclusion, we observed a transient decrease in the plasma concentrations of several biomarkers expressed during plaque destabilization and elevated cardiovascular risk after a single LA treatment.
authors.affiliation: Department of Nephrology and Rheumatology, Georg-August-University Göttingen, Germany.
authors.forename: Julia
authors.initials: J
authors.lastname: Strauchmann
authors.forename: Manuel
authors.initials: M
authors.lastname: Wallbach
authors.forename: Carsten
authors.initials: C
authors.lastname: Bramlage
authors.forename: Miriam
authors.initials: M
authors.lastname: Puls
authors.forename: Stavros
authors.initials: S
authors.lastname: Konstantinides
authors.forename: Gerhard A
authors.initials: GA
authors.lastname: Mueller
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Koziolek
mesh_terms: D000328:Adult; D000368:Aged; D001120:Arginine / Q000031:analogs & derivatives / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001781:Blood Component Removal / Q000379:methods*; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood / Q000302:isolation & purification*; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood; D008875:Middle Aged; D058226:Plaque, Atherosclerotic / Q000628:therapy*; D011266:Pregnancy-Associated Plasma Protein-A / Q000032:analysis; D019010:Vascular Cell Adhesion Molecule-1 / Q000097:blood
chemical_list: D015415:Biomarkers; D008074:Lipoproteins; D019010:Vascular Cell Adhesion Molecule-1; C018524:N,N-dimethylarginine; D002097:C-Reactive Protein; D001120:Arginine; D011266:Pregnancy-Associated Plasma Protein-A; D020780:Matrix Metalloproteinase 9; C579283:PAPPA protein, human
keywords: atherosclerosis; biomarkers; inflammation; lipometabolic disorder; lipoprotein apheresis